Compassionate drug use proposed in Japan

29 April 2007

The compassionate use system for unapproved drugs, which has already been introduced into Europe and the USA, has been proposed by the Japanese Ministry of Health, Labor and Welfare, during the Ministry's study group on rapid supply of effective and safe drugs held earlier this month.

Although unapproved drugs are now available in Japan through private imports by physicians and patients, their authorized compassionate use will allow pharmaceutical manufacturers and importers to officially bring in such medicines, resulting in ensuring safety, quality and efficacy of the products.

The Ministry plans to allow manufacturers, importers, etc, to manufacture, import and market unapproved drugs when these need to be used because there are no alternative medicines and where there is a case of a life-threatening disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight